FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Patients Need To Know What Drugs Do Inside Our Bodies


































Oral therapy Tecfidera (dimethyl fumarate) seems to be emerging as a first-line treatment for relapsing multiple sclerosis – according to Biogen, the company that developed it. That’s good news, and something we need to know.

The company agrees that for some time, the long-term effectiveness and safety of this oral therapy has remained unclear; even exactly how it works has also been largely unknown, as was reported on Multiple Sclerosis News Today. But the company also says that reports released during the last few months offer “encouraging” new findings into the drug’s long-term efficacy and safety; and others are beginning to uncover its workings.

Tecfidera was approved by the U.S. Food and Drug Administration (FDA) in 2013 for the treatment of MS. But, it was not possible then to determine either the effectiveness or the safety in the longer term.

Now, three years later, Biogen is hailing the new research offering “encouraging” findings on both the long-term results of the drug and how it works. Well, that must be promising.

Need to know how drugs work

Ok, I am not a scientist but, as a mere patient, I do see how it is possible for a therapy to be approved for use with only short-term efficacy and safety being known, but I am still concerned that no one had a clear understanding of how it works before it was put out there. Surely, all patients have a right to expect that the scientists and medical professionals know what any drug is going to do inside our bodies.

Biogen announced positive results regarding the long-term effectiveness of Tecfidera during a presentation in April at the 68th annual meeting of the American Academy of Neurology, in Vancouver. The company said that newly diagnosed relapsing MS patients receiving the treatment maintained consistently reduced relapse rates, and that over 50 percent of them exhibited no relapses in six years of treatment. The drug’s long-term safety profile was also supported, the company said..

Now, there is no way that I am going to get involved in the science and technical stuff, which is beyond me. As an MS patient, I just want to know that any new drug is effective and safe to use – and that doctors can explain how it works.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels: ,



Go to Newer News Go to Older News